Bel­lus hit with a set­back as its PhII chron­ic cough drug flops on all 4 dos­es — shares cre­mat­ed on Wall Street

Bel­lus Health says their Phase II study for a new drug to treat chron­ic cough failed, but they al­ready lined up Plan B to help ease the sting with in­vestors.

The biotech test­ed 4 dif­fer­ent dos­es of BLU-5937 in the mid-stage study, all of which fell short of the mark for place­bo-ad­just­ed re­duc­tions in cough­ing — sev­er­al by a wide mar­gin. It al­so didn’t help that there was no clear dose re­sponse in the mix, with a jum­ble of out­comes to re­port. Bel­lus $BLU im­me­di­ate­ly tried to shift fo­cus to a sil­ver lin­ing, not­ing that they hit sta­tis­ti­cal sig­nif­i­cance among a sub­group of “high cough count pa­tients (all pa­tients at or above the base­line me­di­an av­er­age of 32.4 coughs per hour).”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.